ReviewWorld journal of urology2021
Reasons to consider prostatic artery embolization.
Review in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Emergency holmium laser enucleation of the prostate for management of refractory hematuria.World journal of urology · 2026Article
- Predictors of Treatment Failure, Second-Line Therapy Outcomes, and Patient Satisfaction after Prostatic Artery Embolization: A Retrospective Study in Benign Prostatic Hyperplasia.Urologia internationalis · 2026Article
- Quality and impact of youtube for patient education on prostatic artery embolization.Abdominal radiology (New York) · 2025Article
- Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure.Journal of personalized medicine · 2025Article
- Minimally invasive surgical treatments for male lower urinary tract symptoms/benign prostatic enlargement: A review on sexual function outcomes.Bladder (San Francisco, Calif.) · 2025Review
- Value of magnetic resonance angiography before prostatic artery embolization for intervention planning.Scientific reports · 2024Article
- Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization.Turkish journal of urology · 2022Article
- Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization.Diagnostics (Basel, Switzerland) · 2022Article
- Efficacy and Safety of Prostatic Artery Embolization in the Treatment of High Risk Benign Prostatic Hyperplasia and its Influence on Postoperative Life Quality of Patients.Frontiers in surgery · 2022Article
- A Practical Approach for Primary Care Practitioners to Evaluate and Manage Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Review
- TURPxit or not: contemporary management options for benign prostatic obstruction.World journal of urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstatic artery embolization (PAE) has emerged as a truly minimally invasive treatment option for patients with lower urinary tract symptoms presumed secondary to benign prostatic obstruction (LUTS/BPO) over the last few years and is now supported by evidence-based international guidelines. Here, we provide an overview on the profile of PAE based on the most relevant and recent literature.
methodsA comprehensive review of literature on PAE was conducted on PubMed-Medline. The most relevant literature was summarized narratively.
resultsWhile there is still a lack of long-term data, efficacy and safety data have been published for the short to mid-term. As with any minimally invasive technique, relief of bladder outlet obstruction is less pronounced after PAE compared to more invasive resective techniques. This is likely to be associated with higher re-intervention rates during the longer term. However, due to its beneficial safety profile, PAE represents an interesting option for many patients and could fill a niche between pharmacotherapy and formal surgical intervention. Given its unique treatment approach, i.e. endovascular instead of transurethral, PAE has a clearly different profile compared to other minimally invasive treatments. Performance with local anesthesia with possible continuation of anticoagulant drugs and no upper prostate size limit are the most important advantages of PAE.
conclusionPAE represents a valuable supplement in the treatment armamentarium of LUTS/BPH if patients are selected appropriately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.